CB-86, identified by its CAS number 1150586-64-3, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in cancer therapy. It is characterized as a small molecule inhibitor that targets specific pathways involved in tumor growth and proliferation. The compound exhibits a unique structure that allows it to interact selectively with certain proteins, thereby modulating biological processes associated with cancer progression. CB-86 has shown promise in preclinical studies, demonstrating efficacy in inhibiting the growth of various cancer cell lines. Its pharmacological profile suggests a favorable balance between potency and selectivity, which is crucial for minimizing off-target effects. Additionally, ongoing research is focused on understanding its mechanism of action, optimizing its chemical properties, and evaluating its safety and efficacy in clinical settings. As with many investigational compounds, further studies are necessary to fully elucidate its therapeutic potential and to establish appropriate dosing regimens.

CB-
86 is a resorcinol-
anandamide hybrid compound that acts as a partial agonist for the central cannabinoid (CB
1
) receptor and a neutral antagonist for the peripheral cannabinoid (CB
2
) receptor with K
i
values of 5.6 and 7.9 nM, respectively.
1
Its demonstrated potency is similar to that of WIN 55,212-
2 (K
i
= 21 and 2.1 nM for CB
1
and CB
2
, respectively).
1
CB-
86 (1 mg/kg) exhibits antinociceptive effects in mice treated with formalin.
1

CB-86

1150586-64-3: CB-86, identified by its CAS number 1150586-64-3, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in cancer therapy. It is characterized as a small molecule inhibitor that targets specific pathways involved in tumor growth and proliferation. The compound exhibits a unique structure that allows it to interact selectively with certain proteins, thereby modulating biological processes associated with cancer progression. CB-86 has shown promise in preclinical studies, demonstrating efficacy in inhibiting the growth of various cancer cell lines. Its pharmacological profile suggests a favorable balance between potency and selectivity, which is crucial for minimizing off-target effects. Additionally, ongoing research is focused on understanding its mechanism of action, optimizing its chemical properties, and evaluating its safety and efficacy in clinical settings. As with many investigational compounds, further studies are necessary to fully elucidate its therapeutic potential and to establish appropriate dosing regimens.

CAS 1150586-64-3

CB-86

CB-86

Ref: TR-C227093